Eleven Biotherapeutics
March 1, 2017
PDF
Add to Briefcase

Eleven Biotherapeutics to Present at Upcoming Investor Conferences in March

 

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences. Details are as follows:

Cowen and Company 37th Annual Health Care Conference

Date: Wednesday, March 8, 2017

Time: 8:00 a.m. ET

Location: Boston, MA

 

 

29th Annual Roth Conference

Date: Tuesday, March 14, 2017

Time: 2:30 p.m. PT (5:30 p.m. ET)

Location: Dana Point, CA
 

A live webcast of both events will be available under "Events & Presentations" in the Investors & Media section of Eleven's website, www.elevenbio.com. An archived replay of the presentations will be available on the Company's website approximately one hour after the live events and will be available for 90 days following the presentations.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. The Company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information please refer to the Company's website at www.elevenbio.com.

 

Stern Investor Relations
Hannah Deresiewicz
hannahd@sternir.com

Source: Eleven Biotherapeutics, Inc.

 

 

News Provided by Acquire Media